CURE Media Group, the nation’s leading digital and print media enterprise dedicated to patients and survivors of cancer, will launch its first television commercial featuring curetoday.com during the Stand Up To Cancer (SU2C) telecast tonight.
CURE Media Group, the nation’s leading digital and print media enterprise dedicated to patients and survivors of cancer, will launch its first television commercial featuring curetoday.com during the Stand Up To Cancer (SU2C) telecast tonight, announced Michael J. Hennessy Jr., president of MJH Associates, Inc., parent company of CURE Media Group. The commercial aims to give individuals with cancer a platform to voice how they are more than just patients.
“We are so honored to be recognized during the Stand Up To Cancer (SU2C) telecast,” said Michael J. Hennessy Jr., in making the announcement. “This is a huge achievement for the CURE Media Group and we are so thankful to get our message across airing our first commercial.”
CURE® message, “Today, I’m more than a patient,” will fill millions of screens during SU2C’s sixth biennial televised fundraising special. CURE® hopes viewers will share how they are more than a patient, using the hashtag #MoreThanAPatient on social media.
The commercial will air on CBS in New York, San Francisco and Boston on Friday, Sept. 7 at 8 p.m. ET/PT and 7 p.m. CT.
To see the commercial after it airs, visit http://www.curetoday.com or find us on Twitter @cure_magazine, Facebook @curemagazine or Instagram @curetoday.
MLB VP Reveals Cancer Diagnosis, Jaxon-Smith Njigba Raises Awareness for Cancer Foundation and More
December 8th 2023As Billy Bean, MLB VP, revealed a cancer diagnosis and Toronto Blue Jays sportscaster, Jamie Campbell showed pre-skin cancer photo, here is what’s happening in the oncology space this week.
Read More
Fertility Research ‘Long Overdue’ for Patients With Cervical Cancer
November 30th 2023Cervical cancer survivor Kate Weissman talks recent research on follow-up visits for patients after fertility-sparing surgery, and explains why it’s ‘something that the cervical cancer community is owed.’
Listen
Dato-DXd Extends PFS in HR+/HER2- Inoperable or Metastatic Breast Cancer
December 7th 2023Dato-DXd (datopotamab deruxtecan) as a form of treatment compared to chemotherapy resulted in improved progression-free survival for patients with previously treated hormone receptor-positive/HER2-negative inoperable or metastatic breast cancer.
Read More